Literature DB >> 3050686

ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery.

R H Brown1, R H Stewart, M G Lynch, A S Crandall, A I Mandell, J T Wilensky, A L Schwartz, D E Gaasterland, J M DeFaller, E J Higginbotham.   

Abstract

The effect of an alpha adrenergic agonist, ALO 2145 (para-amino-clonidine [PAC]), was examined in a double-masked, multicenter study on the postoperative intraocular pressure (IOP) elevation after laser surgery in 165 patients (83 trabeculoplasty, 36 iridotomy, and 46 capsulotomy). One drop of 1.0% ALO 2145 or vehicle was instilled 1 hour before and immediately after laser surgery. The mean IOP increase in the ALO 2145-treated group was lower (P less than 0.05) than in the placebo group at each of the first three postoperative hours. Overall, 18% of placebo-treated eyes experienced IOP increases greater than or equal to 10 mmHg as compared with 4% of ALO 2145-treated eyes (P less than 0.003). Ocular and systemic side effects were minimal and did not differ between the treatment groups. ALO 2145 safely and effectively reduced the incidence and magnitude of potentially harmful IOP elevations after anterior segment laser surgery.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3050686     DOI: 10.1016/s0161-6420(88)33185-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

1.  The role of apraclonidine hydrochloride in laser therapy for glaucoma.

Authors:  A L Robin
Journal:  Trans Am Ophthalmol Soc       Date:  1989

2.  The role of prostaglandins in the para-aminoclonidine-induced reduction of intraocular pressure.

Authors:  R F Wang; C B Camras; S M Podos; K W Lee; K C Bhuyan; D K Bhuyan
Journal:  Trans Am Ophthalmol Soc       Date:  1989

Review 3.  Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.

Authors:  Chihiro Mayama; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-01-16       Impact factor: 2.447

4.  Prophylactic use of acetazolamide to prevent intraocular pressure elevation following Nd-YAG laser posterior capsulotomy.

Authors:  I D Ladas; G P Pavlopoulos; S N Kokolakis; G P Theodossiadis
Journal:  Br J Ophthalmol       Date:  1993-03       Impact factor: 4.638

5.  Long term effect of apraclonidine.

Authors:  S V Araujo; J B Bond; R P Wilson; M R Moster; C M Schmidt; G L Spaeth
Journal:  Br J Ophthalmol       Date:  1995-12       Impact factor: 4.638

6.  Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.

Authors:  A L Robin; R Ritch; D Shin; B Smythe; T Mundorf; R P Lehmann
Journal:  Trans Am Ophthalmol Soc       Date:  1995

Review 7.  Pharmacological advances in the treatment of glaucoma.

Authors:  J B Serle
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

8.  Prevention of the immediate intraocular pressure rise following argon laser trabeculoplasty.

Authors:  T W Metcalfe; D E Etchells
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

9.  Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers.

Authors:  N Yüksel; C Güler; Y Caglar; O Elibol
Journal:  Int Ophthalmol       Date:  1992-09       Impact factor: 2.031

10.  Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate.

Authors:  A L Robin; A L Coleman
Journal:  Trans Am Ophthalmol Soc       Date:  1990
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.